TY - JOUR
T1 - Senescent cells
T2 - An emerging target for diseases of ageing
AU - Childs, Bennett G.
AU - Gluscevic, Martina
AU - Baker, Darren J.
AU - Laberge, Remi Martin
AU - Marquess, Dan
AU - Dananberg, Jamie
AU - Van Deursen, Jan M.
N1 - Publisher Copyright:
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Chronological age represents the single greatest risk factor for human disease. One plausible explanation for this correlation is that mechanisms that drive ageing might also promote age-related diseases. Cellular senescence, which is a permanent state of cell cycle arrest induced by cellular stress, has recently emerged as a fundamental ageing mechanism that also contributes to diseases of late life, including cancer, atherosclerosis and osteoarthritis. Therapeutic strategies that safely interfere with the detrimental effects of cellular senescence, such as the selective elimination of senescent cells (SNCs) or the disruption of the SNC secretome, are gaining significant attention, with several programmes now nearing human clinical studies.
AB - Chronological age represents the single greatest risk factor for human disease. One plausible explanation for this correlation is that mechanisms that drive ageing might also promote age-related diseases. Cellular senescence, which is a permanent state of cell cycle arrest induced by cellular stress, has recently emerged as a fundamental ageing mechanism that also contributes to diseases of late life, including cancer, atherosclerosis and osteoarthritis. Therapeutic strategies that safely interfere with the detrimental effects of cellular senescence, such as the selective elimination of senescent cells (SNCs) or the disruption of the SNC secretome, are gaining significant attention, with several programmes now nearing human clinical studies.
UR - http://www.scopus.com/inward/record.url?scp=85030756466&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030756466&partnerID=8YFLogxK
U2 - 10.1038/nrd.2017.116
DO - 10.1038/nrd.2017.116
M3 - Review article
C2 - 28729727
AN - SCOPUS:85030756466
SN - 1474-1776
VL - 16
SP - 718
EP - 735
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 10
ER -